We and others have demonstrated that PTPRO is capable of dephosphorylating RTKs such as ERBB2 and EPH receptors (Shintani et al., 2006; Dong et al., 2017a) and repressing tumor growth (Motiwala et al., 2003; Motiwala et al., 2004; Dong et al., 2017a). Here, ERBB2 is linked to neoplasm.